Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 2

Status

Active not recruiting 5Terminated 4Completed 4Withdrawn 3

Sponsor Class

OTHER 1NIH 1FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2CNS 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Prostatic Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × copanlisib × Clear all
NCT05687721 2025-06-15

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

VA Office of Research and Development

Phase 1/2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT06218667 2024-10-31

A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT03803761 2023-09-25

A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡